WALTHAM, MA – Snapdragon Chemistry announced a large-scale expansion of its
Waltham facility, with a state-of-the-art good manufacturing practices (GMP) facility opening later this year at 360 Second Avenue, just down the street from the company’s existing headquarters.
The new 51,000 square foot facility will enable Snapdragon to manufacture experimental pharmaceutical products for human clinical trials, building off of the industry-leading research and development done at its headquarters. It will also add at least 50 jobs to the company’s expanding workforce in the coming years.
“Our company is built on innovation and tackling some of most difficult problems in chemical manufacturing,” said Matthew Bio, President and CEO of Snapdragon Chemistry. “Opening a world-class drug manufacturing facility during the ongoing COVID-19 pandemic is no small feat, but it is a testament to the incredible work of our team and partners. The facility at 360 Second Ave. will enable us to supply experimental medicines for clinical
trials. It was important for us to have manufacturing here in Massachusetts, co-located with the world’s highest concentration of pharmaceutical and biotech companies. Medicines discovered here can also be manufactured here with the goal of shortening the time it takes to get to patients.”
Snapdragon partnered with CRB Group, a design/build firm that has built plants for some of the world’s largest pharmaceutical companies and in 2019 was ranked the number three top pharmaceutical design firm by Engineering News-Record, underscoring Snapdragon’s commitment to quality and pursuing the state-ofthe-art in chemical manufacturing.
“CRB is excited to partner with Snapdragon Chemistry to bring their vision to reality. This technical project is required to adhere to strict pharmaceutical and safety regulations,” said CRB Project Director Darren Fritsch. “We have engaged our ONEsolutionTM design and build team to meet those quality requirements as well as Snapdragon’s schedule and budget needs.”
The new space features numerous, flexible manufacturing suites, purpose-built for advanced continuous manufacturing but adaptable to enable batch methods as well. Snapdragon’s proprietary technologies will enable manufacturing with a high degree of automation and process fidelity resulting in high quality product, delivered rapidly.
The expansion will lead Snapdragon to nearly double its workforce in the next few years, at a time of already phenomenal growth. The company has close to doubled its revenue in nearly every year since 2016. The new manufacturing facility will help further that success, providing new job opportunities in technical manufacturing, quality control, and operations. The facility at 360 Second Avenue is scheduled to open in the fourth quarter of 2021.
